UOC
ALXN

UBS O'Connor’s Alexion Pharmaceuticals ALXN Stock Holding History

UBS O'Connor’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,428,122
Closed -$813M – 1066
2021
Q2 		$813M Buy
4,428,122
+2,861,349
+183% +$491M 7.26% 2
2021
Q1 		$240M Buy
1,566,773
+1,017,152
+185% +$157M 3.45% 6
2020
Q4 		$85.9M Buy
+549,621
New +$70.6M 1.75% 9
2016
Q2 		– Sell
-10,010
Closed -$1.39M – 543
2016
Q1 		$1.39M Buy
+10,010
New +$1.47M 0.03% 296

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

UBS O'Connor's ALXN Position: Q3 2021 in Review

UBS O'Connor sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,428,122 shares — an estimated $813M sold.

UBS O'Connor first reported a position in ALXN in Q1 2016 and held it in 4 quarters. The position peaked at $813M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • UBS O'Connor reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • UBS O'Connor sold 4,428,122 Alexion Pharmaceuticals shares in Q3 2021, an estimated $813M.
  • UBS O'Connor first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • UBS O'Connor's Alexion Pharmaceuticals position peaked at $813M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on UBS O'Connor's 13F filing for Q3 2021, filed 12 Nov 2021.